David Lieberman
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1457397770
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Acadia Pharmaceuticals Inc accounts for 77.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $8,801, 5.2 times the $1,703 reported in 2019. Among neurology with special qualifications in child neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $432.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$14K
- GW Research Limited$2K
- Ionis Pharmaceuticals, Inc.$2K
- EMD Serono, Inc.$542
- AbbVie$194
- Neurelis, Inc.$135
- plus $37 from 1 others
Across 222 payments — averaging $4161.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$661K
- GW Research Limited$145K
- Jazz Pharmaceuticals Inc.$118K
What the payments were for
- Consulting fees$9,79253%
- Speaking & faculty fees$4,70025%
- Travel & lodging$2,67714%
- Food & beverage$1,4298%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 18 | $14,394 |
| GW Research Limited | 7 | $1,703 |
| Ionis Pharmaceuticals, Inc. | 13 | $1,613 |
| EMD Serono, Inc. | 1 | $542 |
| AbbVie(2 entities) | 2 | $194 |
| Neurelis, Inc. | 1 | $135 |
| Astellas Pharma US Inc | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,618 in reported general payments places this provider in the 90th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LevocarnitineLevocarnitine (With Sugar) | 18 | $1,660 |
| Levetiracetam | 14 | $904 |
| Ziprasidone Hcl | 20 | $490 |
| Divalproex Sodium | 14 | $476 |
| Guanfacine Hcl ErGuanfacine Hcl | 22 | $423 |
| Sertraline Hcl | 40 | $246 |
| Trazodone Hcl | 22 | $83 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Boston
- Elizabeth ThieleBoston$278K
- Jurriaan PetersBoston$265K
- Basil DarrasBoston$253K
- Kiran MaskiBoston$105K
- Phillip PearlBoston$50K
- Alexander RotenbergBoston$34K
- Irina AnselmBoston$30K
- Nicole UllrichBoston$26K
- Robert StoweBoston$9K
- Siddharth SrivastavaBoston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.